Business Context and Reporting Period
This Form 8-K is a current report filed by Biorestorative Therapies, Inc. (Nasdaq: BRTX) on May 1, 2026. The filing discloses the approval of cash bonuses for executive officers for the fiscal year ended December 31, 2025, by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on executive compensation data for the fiscal years 2024 and 2025.
| Named Executive Officer | Position | 2025 Total Compensation | 2024 Total Compensation |
|---|---|---|---|
| Lance Alstodt | Chief Executive Officer | $2,409,167 | $1,314,583 |
| Francisco Silva | VP, Research and Development | $2,322,916 | $1,227,083 |
| Robert Kristal | Chief Financial Officer | $801,750 | $683,752 |
Note: 2025 compensation includes significant option awards and discretionary bonuses to be paid in 2026.
Material Changes
- Compensation Increase: Total compensation for all three Named Executive Officers increased significantly in 2025 compared to 2024, driven primarily by higher option awards and increased discretionary bonuses.
- CEO Compensation: Lance Alstodt's total compensation rose from $1,314,583 in 2024 to $2,409,167 in 2025.
- Option Awards: Option awards for the CEO increased from $500,000 in 2024 to $1,512,500 in 2025.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies. The document is strictly a disclosure of compensatory arrangements approved on May 1, 2026.
Investor Verification Checklist
- Verify the grant date fair value assumptions for the 2025 option awards referenced in Note 6 of the Annual Report.
- Confirm the cash flow impact of the 2025 discretionary bonuses, which are scheduled to be paid in 2026.
- Review the full Annual Report (10-K) for the fiscal year ended December 31, 2025, to assess the company's overall financial health and revenue performance, as this 8-K does not contain those figures.